23 results
8-K
EX-99.2
STSA
Satsuma Pharmaceuticals Inc
20 Dec 22
Satsuma Pharmaceuticals Provides STS101 Development Program and Corporate Update
4:19pm
% -na- Congestion 3.1% / 4.9% 15% -19.7% -na- Package-related injury / laceration 0% / 0% 1.7% ?? % of subjects who withdrew from open- 4.1% (ASCEND … Laceration risk from metal band on vial; in Impel Ph3 safety trial, 2-3% of subjects reported ”Package-associated injury.” FDA AE reporting system contains
8-K
EX-99.1
STSA
Satsuma Pharmaceuticals Inc
30 Nov 22
Other Events
4:00pm
expert legal-regulatory consultants, we are confident the STS101 data package can support NDA filing and potential approval and believe there is strong
8-K
EX-99.2
onqho9hodi x0p5b6r5m
1 Mar 21
Satsuma Pharmaceuticals Announces Updated STS101 Development Plan
12:00am
DEF 14A
yff0bdn hmu
24 Apr 20
Definitive proxy
4:14pm
10-K
6lwnjion
10 Mar 20
Annual report
4:20pm
424B4
7srx0amz
13 Sep 19
Prospectus supplement with pricing info
5:08pm
S-1/A
shpnu2
3 Sep 19
IPO registration (amended)
6:12am
S-1/A
EX-1.1
pb5ku7wu4a1yg6
3 Sep 19
IPO registration (amended)
6:12am
CORRESP
eitn624
3 Sep 19
Correspondence with SEC
12:00am
S-1
sbtsp1y
16 Aug 19
IPO registration
5:15pm
CORRESP
hfvizgxgrnboum7of9
16 Aug 19
Correspondence with SEC
12:00am